
Company valuation, historical trends, and peer comparisons.
According to Gilead Sciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 236.14B. This represents a change of 27.22% compared to the average of 185.62B of the last 4 quarters.
The mean historical Enterprise Value of Gilead Sciences, Inc. over the last ten years is 118.04B. The current 236.14B Enterprise Value has changed 100.06% with respect to the historical average. Over the past ten years (40 quarters), GILD's Enterprise Value was at its highest in in the September 2026 quarter at 204.91B. The Enterprise Value was at its lowest in in the December 2018 quarter at 90.07B.
Average
118.04B
Median
116.80B
Minimum
90.57B
Maximum
170.06B
Discovering the peaks and valleys of Gilead Sciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 28.93%
Maximum Annual Enterprise Value = 170.06B
Minimum Annual Increase = -27.55%
Minimum Annual Enterprise Value = 90.57B
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 170.06B | 28.93% |
| 2024 | 131.91B | 9.92% |
| 2023 | 120.00B | -5.92% |
| 2022 | 127.56B | 13.33% |
| 2021 | 112.56B | 14.11% |
| 2020 | 98.64B | 3.30% |
| 2019 | 95.49B | 5.43% |
| 2018 | 90.57B | -24.26% |
| 2017 | 119.59B | 4.90% |
| 2016 | 114.00B | -27.55% |
The current Enterprise Value of Gilead Sciences, Inc. (GILD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
140.66B
5-year avg
132.42B
10-year avg
118.04B
Gilead Sciences, Inc.’s Enterprise Value is less than Merck & Co., Inc. (415.14B), less than Pfizer Inc. (236.34B), greater than GSK plc (96.50B), less than Johnson & Johnson (692.93B), greater than Sanofi (117.98B), less than AstraZeneca PLC (318.95B), less than Novartis AG (350.28B), less than Roche Holding AG (299.56B), less than Eli Lilly and Company (1.38T), less than AbbVie Inc. (591.13B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 415.14B | $370.91B | |
| 236.34B | $175.49B | |
| 96.50B | $103.68B | |
| 692.93B | $665.19B | |
| 117.98B | $113.74B | |
| 318.95B | $293.13B | |
| 350.28B | $311.59B | |
| 299.56B | $388.50B | |
| 1.38T | $1.33T | |
| 591.13B | $521.00B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gilead Sciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gilead Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Gilead Sciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Gilead Sciences, Inc. (GILD)?
What is the 3-year average Enterprise Value for Gilead Sciences, Inc. (GILD)?
What is the 5-year average Enterprise Value for Gilead Sciences, Inc. (GILD)?
How does the current Enterprise Value for Gilead Sciences, Inc. (GILD) compare to its historical average?